Navigation Links
Bradmer announces new additions to management team
Date:4/2/2008

- Appoints Jukka Karjalainen M.D., Ph.D. to the position of Chief Operating and Medical Officer and Robert Tuttle, Ph.D.to the position of Senior

Vice-President Manufacturing -

TSX: BMR

TORONTO, April 2 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that it has appointed Jukka Karjalainen, M.D., Ph.D. to the position of Chief Operating and Medical Officer and Robert Tuttle, Ph.D. to the position of Senior Vice-President Manufacturing.

"Dr. Karjalainen's experience in late stage drug development and commercialization and Dr. Tuttle's experience with commercial manufacturing will be crucial as we complete the final preparations to initiate our Phase III trial for Neuradiab," said Alan M. Ezrin, Ph.D., President and CEO of Bradmer Pharmaceuticals. "Appointing Dr. Karjalainen and Dr. Tuttle to our executive team demonstrates our ability to attract key people who are able to support our progress as we enter a multi-center clinical setting complete with cGMP grade material and support plans for the execution of our trial."

Dr. Karjalainen has extensive medical expertise, international pharmaceutical and clinical trial experience. He has played a key role in all phases of drug development and commercialization at both private and public companies. Most recently, he was Vice President, Drug Development at Cytochroma where he led drug development in Dermatology, Kidney Disease, and Oncology. He held the position of Director, Medical & Regulatory Affairs at Biovail, and was Medical Director at Eli Lilly & Company in Finland. Dr. Karjalainen also spent three years as Research Manager and Core Clinician with Leiras Inc. and Schering AG respectively. Dr. Karjalainen received his M.D. in 1983 and Ph.D. in 1989 from the University of Oulu, Finland where he is an Associate
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
2. Notice of Bradmer Pharmaceuticals Conference Call
3. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
4. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
5. Bradmer announces additions to Scientific Advisory Board
6. Bradmer Medical Isotope Supply For Phase III Trial Secure
7. Bradmer to present at Rodman & Renshaw Healthcare Conference
8. Bradmer provides Phase III Neuradiab trial update and guidance
9. Bradmer announces management changes
10. Crdentia Announces 2007 Fourth Quarter Results
11. Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2008 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...ising incidence of obesity could counter recent in... 2 (HealthDay News) -- The overall health of the U...cades, largely because people have quit smoking in...t soon be wiped out if the rising obesity rates am...rent trends in both smoking and obesity continue u...
(Date:12/2/2009)...hes now available, many more to come, NIH director... News) -- Thirteen stem cell lines have been adde...-funded research, and many more such lines will so...ced Wednesday. , These are the first additional...unded by the U.S. National Institutes of Health (N...
(Date:12/2/2009)...WHITE PLAINS, N.Y., Dec. 2 /PRNewswire-USNewswire/... their findings in blood cancer research at the an...ce in New Orleans December 4-8, 2009. ,, Throu...oma Society (LLS) experts, including Chief Medical...esident of Patient Services Hildy Dillon, and Vice...
(Date:12/2/2009)...PHILADELPHIA, Dec. 2 Independence ...nefits contract with Lincoln Financial Group. IBC ...or approximately 10,000 Lincoln Financial Group em... nation. The Lincoln plan offerings will include t...s. ,, "I know I speak for all of us at Independ...
(Date:12/2/2009)...Joseph Balboni loves sports. An avid tennis player...old insurance agent became increasingly frustrated...us, a degenerative eye disorder. Unable to return ... he faced the prospect of a corneal transplant to ... years ago, Balboni discovered an alternative trea...
Breaking Medicine News(10 mins):Health News:Health Gains From Lowered Smoking Rates in Jeopardy 2Health News:Health Gains From Lowered Smoking Rates in Jeopardy 3Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 2Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 3Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 2Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 3Health News:Brandeis studies evaluate visionary approach to improving eyesight 2
... Infections during the first year of life are a ma...s of arthritis later in life, according to new res...he Annual Congress of the European League Against ...irst birthday had an increased likelihood of devel...
...he issue of selling kidneys. , A regulated system...tion to the growing shortage of kidneys for transp...ry at the University of Minnesota. , In many are...is the annual death rate for suitable transplant c...
...pedics, Inc., a,leader in orthopedic extremity imp...ecutives, William F. Warrender, Jr., John F. Walte...s. Their extensive background and,experience will ...les. He brings more than 25 years of sales, market...
...Certain single nucleotide polymorphisms (SNPs) wit...region are shown to be associated with juvenile id... of two independent cohorts presented today at EUL... genetic code), rs2104286, rs41295061 and rs115946...
... WASHINGTON, June 13 A team of professionals,fro...to Germany on Saturday,to work with the US Army,s ...ng their current rehabilitation practices. They wi...tation,services. The ERMC operates 15 ambulatory c...
... try to resolve remaining issues, TORONTO, June 1...pany,PreMD Inc. (TSX: PMD; Amex: PME) today announ... the U.S. Food and Drug Administration (FDA) in an...next 60 days PreMD and the FDA will work together ...
Other Medicine News:Health News:Early life infections increase the risk of rheumatoid arthritis and juvenile idiopathic arthritis 2Health News:What's wrong with selling kidneys? 2Health News:Three Industry Veterans Join Ascension Orthopedics 2Health News:Three Industry Veterans Join Ascension Orthopedics 3Health News:Specific mutations in the IL2RA gene associated with juvenile idiopathic arthritis 2Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 2Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 3Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 4Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 5Health News:PreMD Reports Further Positive Meetings with the FDA 2
(Date:12/2/2009)..., , EAST HANOVER, N.J., Dec. 2 /PRNe... including a late-breaking presentation on Tasigna...ronic myeloid leukemia, demonstrate the strength o...the care of patients. ,, The new data, at the ...eeting and Exposition, highlight the company,s cur...
(Date:12/1/2009)..., , TEMECULA, Calif., Dec. 1 /PRNewswire-Fir...Bulletin Board: PSTX) announced today that it has ...f Chief Financial Officer, Treasurer and Corporate...ting CFO since 2008. Prior to joining Patient Saf...t Finance, Chief Financial Officer, Treasurer and ...
(Date:12/1/2009)..., , REDONDO BEACH, Calif., Dec. 1 /PRNewswire...ounces their Elective Single Embryo Transfer (eSET...entive for patients with good embryo quality and a...he chance of twins by transferring a single embryo... technology today is reducing the number of multip...
Breaking Medicine Technology:Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Patient Safety Technologies, Inc. Appoints Marc L. Rose, CPA (PA), Chief Financial Officer 2Reproductive Partners Announces Elective Single Embryo Transfer (eSET) Encouragement Program 2GSK Advisory 3A Warehouse Theft 55192 1GSK Advisory 3A Warehouse Theft 55192 2American Lung Association in Minnesota 3A Motorists Can Get 85 Cents a Gallon E85 Fuel in Woodbury Minn 55189 1AMERIGROUP Corporation to Host Investor Day 55187 1
...ty of Hematology (ASH) and the American Society of... joint guideline on the use of,erythropoiesis-stim...late,the bone marrow to produce more red blood cel...oal of these guidelines is to inform clinicians wi...studies regarding the risks and,benefits of ESAs i...
...pplications for RNAi, WALTHAM, Mass., Oct. 22 Th...ld leader in serving science, has,collaborated wit...echnology,platform that expands applications for R...sciences research, including neuroscience, immunol...d Thermo Scientific Dharmacon(R),SMARTvector(TM) s...
Other Medicine Technology:ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients 2ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients 3Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research 2Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research 3
Shepard Bipolar Forceps Straight
Shepard Bipolar Forceps Angled
McCullough Bipolar Forceps
Dean Tonsil Knife
Medicine Products: